Skip to main content Skip to footer
The life sciences industry is undergoing a seismic transformation through advancements in traditional and generative AI. In this interview, David Staunton shares insights gained from working with leading pharma manufacturing clients on real-world applications of AI, including accelerating drug discovery; reducing drug development costs; creating digital twins with greater accuracy; and forecasting and executing faster supply chain decisions. 
“Every single aspect from early discovery through to launch, through manufacturing and commercial, are completely changing as a direct result of AI.”

David Staunton


Related thought leadership


Traditional and gen AI: an insight into the new normal for pharma firms

Hear how AI is changing the game for pharma companies, from early discovery to commercialization.

A machine filling tubes


How life sciences can ride the AI wave to competitive success

Discover how to harness AI to create competitive advantage without also creating unforeseen risk.

An FT Live Interview


Gen AI for biopharma: 5 less obvious truths

Five core truths are revealed on how to create value-driven, scalable generative AI programs that turn into a multi-year competitive advantage.

A structure like DNA


New work, new world, generative AI report

Read our recent generative AI economics model with Oxford Economics to hear the latest projections of AI’s impact on the workforce.

New work, new world

Ready to learn more?

Find out how Cognizant can help life sciences manufacturing organizations move into the digital age.